Company intelligence / Profile preview

IMPACT Therapeutics

Shanghai / Pudong New Area, Shanghai, Chinaimpacttherapeutics.com ↗

Ownership: Private
Employees: ~70
Development stage: Commercial

Overview

IMPACT Therapeutics has developed a robust pipeline of targeted anti-cancer therapeutics based on the principle of synthetic lethality. Its lead product, Senaparib (IMP4297), a novel PARP inhibitor, achieved best-in-class efficacy and safety in a pivotal Phase III trial for first-line maintenance therapy in advanced ovarian cancer. The drug received marketing authorization from China's NMPA in January 2025. Other assets include WEE1 and ATR inhibitors in global Phase I trials and next-generation PARP1-selective inhibitors entering early clinical development[4][8].

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

10 assets

senaparib

9 more assets in the full pipeline.

Request access →

Partnerships

Huadong Medicine – commercialization partner for Senaparib in China[8].Eikon Therapeutics – global license/collaboration on next-gen PARP inhibitors excluding Greater China[4].

Beyond the preview

Go deeper on IMPACT Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMPACT Therapeutics.

Explore the full profile